Report Sections

See All Reports

  • HP:0000819: Diabetes mellitus
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0000819: Diabetes mellitus

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (58)


    Name (Synonyms) Correlation
    drug3465 Two doses of placebo at the schedule of day 0,28 Wiki 0.28
    drug3454 Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 Wiki 0.28
    drug3451 Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 Wiki 0.28
    Name (Synonyms) Correlation
    drug2391 Peer Mentor Delivery Wiki 0.20
    drug2443 Pioglitazone 30 mg Wiki 0.20
    drug3448 Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 Wiki 0.20
    drug3497 Use of Facetime with child and parents during induction Wiki 0.20
    drug3457 Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 Wiki 0.20
    drug3447 Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule Wiki 0.20
    drug1351 Glycaemic levels Wiki 0.20
    drug3500 Use of the pinpointIQ solution (physIQ, Inc.) Wiki 0.20
    drug3482 Ultrasound of the lower limbs Wiki 0.20
    drug1792 Linagliptin 5 MG Wiki 0.20
    drug3679 antidiabetic treatment Wiki 0.20
    drug3551 Videofluoroscopic Swallowing Study (VFSS) Wiki 0.20
    drug3438 Tuberculin test Wiki 0.20
    drug3507 V-SARS Wiki 0.20
    drug3900 no interventional study Wiki 0.20
    drug3459 Two doses of placebo at the emergency vaccination schedule Wiki 0.20
    drug1007 DiaBetter Together Wiki 0.20
    drug3539 VentaProst (inhaled epoprostenol delivered via a dedicated delivery system) Wiki 0.20
    drug3446 Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule Wiki 0.20
    drug3517 VITROS Anti-SARS-CoV-2 IgG test Wiki 0.20
    drug1454 Hospital: Usual Care (UC) Wiki 0.20
    drug3608 Weight Counseling Wiki 0.20
    drug3537 Venous blood was collected for biochemistry testing Wiki 0.20
    drug3526 Vaginal fluid Covid-19 PCR test Wiki 0.20
    drug1874 MANAGEMENT OF COVID-19 Wiki 0.20
    drug3458 Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly Wiki 0.20
    drug3584 Viusid and Asbrip Wiki 0.20
    drug3453 Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule Wiki 0.20
    drug3468 UB-612 Wiki 0.20
    drug3802 hospitalisation, necessity of ICU, mortality rate, lung involvement Wiki 0.20
    drug3445 Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 Wiki 0.20
    drug1665 Intervention for TECC Model Wiki 0.20
    drug1827 Lovenox 40 MG in 0.4 mL Prefilled Syringe Wiki 0.20
    drug1005 Dexcom G6 Wiki 0.20
    drug3460 Two doses of placebo at the routine vaccination schedule Wiki 0.20
    drug2183 No interventions Wiki 0.20
    drug3277 Tele-interventions related to diabetes management and mental well-being Wiki 0.20
    drug3547 Video based aerobic exercise Wiki 0.20
    drug1915 Mannitol Wiki 0.20
    drug3550 Video-Based intervention Wiki 0.20
    drug3555 Views and experiences of health care professionals working in intensive care units during the COVID-19 pandemic Wiki 0.20
    drug3525 Vaccine coverage assessment Wiki 0.20
    drug1453 Hospital: DD-CA Wiki 0.20
    drug3452 Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule Wiki 0.20
    drug3521 VXA-CoV2-1 Wiki 0.20
    drug3491 Unfractionated heparin Wiki 0.14
    drug2731 RTB101 Wiki 0.14
    drug675 Canakinumab Wiki 0.14
    drug3897 no intervention Wiki 0.13
    drug4025 standard of care Wiki 0.12
    drug3285 Telemedicine Wiki 0.10
    drug2276 Online Survey Wiki 0.09
    drug3574 Vitamin D Wiki 0.06
    drug1472 Hydroxychloroquine Wiki 0.02
    drug2448 Placebo Wiki 0.02

    Correlated MeSH Terms (10)


    Name (Synonyms) Correlation
    D003920 Diabetes Mellitus, NIH 0.98
    D003922 Diabetes Mellitus, Type 1 NIH 0.47
    D003924 Diabetes Mellitus, Type 2 NIH 0.40
    Name (Synonyms) Correlation
    D044882 Glucose Metabolism Disorders NIH 0.28
    D008659 Metabolic Diseases NIH 0.23
    D004700 Endocrine System Diseases NIH 0.14
    D008107 Liver Diseases NIH 0.07
    D012140 Respiratory Tract Diseases NIH 0.04
    D018352 Coronavirus Infections NIH 0.04
    D045169 Severe Acute Respiratory Syndrome NIH 0.03

    Correlated HPO Terms (4)


    Name (Synonyms) Correlation
    HP:0100651 Type I diabetes mellitus HPO 0.49
    HP:0005978 Type II diabetes mellitus HPO 0.40
    HP:0000818 Abnormality of the endocrine system HPO 0.14
    Name (Synonyms) Correlation
    HP:0001392 Abnormality of the liver HPO 0.08

    Clinical Trials

    Navigate: Correlations   HPO

    There are 25 clinical trials


    1 A Patient-Centered PaTH to Addressing Diabetes: Impact of State Health Policies on Diabetes Outcomes and Disparities

    The overarching goal of this proposal is to understand the comparative effectiveness of obesity counseling as covered by CMS in improving weight loss for adults either with or at high risk of type 2 diabetes. CMS and most insurers now include obesity screening and counseling benefits, with no cost sharing to patients. Since overweight patients are at highest risk for diabetes, improved weight management services could prevent diabetes and its negative health outcomes. Beneficiaries with obesity are eligible for up to 20 face-to-face visits for weight counseling in the primary care setting. The investigators propose comparing weight and diabetes outcomes in three states using EHR and claims data before and after this policy was implemented by leveraging the novel infrastructure of the Patient-Centered Outcomes Research Institute-funded PaTH Clinical Data Research Network. Following developments during the COVID-19 pandemic, the investigators further plan to leverage our study infrastructure across five health systems to understand the comparative effectiveness of telemedicine approaches for providing outpatient care for patients with or at risk of type 2 diabetes and how these approaches impact the subgroup of patients with COVID-19.

    NCT02788903
    Conditions
    1. Obesity
    2. Diabetes
    3. Covid19
    Interventions
    1. Other: Weight Counseling
    2. Other: Telemedicine
    MeSH:Diabetes Mellitus
    HPO:Diabetes mellitus

    Primary Outcomes

    Description: Weight change during counseling and/or % of weight change during program and maintained over remaining time period will be assessed in both the diabetes and pre-diabetes cohorts.

    Measure: Weight change

    Time: 10 years

    Secondary Outcomes

    Description: In the pre-diabetes cohort, diabetes incidence will be determined as the % of patients who develop diabetes following weight counseling. In the diabetes cohort, uncontrolled diabetes will be measured.

    Measure: Diabetes Incidence

    Time: 10 years

    Description: Incidence of hospitalization will be assessed for COVID-19 positive patients

    Measure: Hospitalization

    Time: 1 year

    Description: Incidence of intubation will be assessed for COVID-19 positive patients

    Measure: Intubation

    Time: 1 year

    Description: Incidence of death will be assessed for COVID-19 positive patients

    Measure: Death

    Time: 1 year
    2 DiaBetter Together: A Strengths-based, Peer Mentor Transition RCT for Young Adults With Type 1 Diabetes

    DiaBetter Together is a strengths-based peer support intervention delivered to young adults (age 17-25) by trained Peer Mentors (age 20-35) during the transition between pediatric and adult diabetes care. The aims of this proposed randomized controlled trial are to evaluate the impact of the intervention on glycemic control (primary), time to first adult care visit, adherence, and psychosocial outcomes (secondary) in young adults with T1D after 12 months.

    NCT04247620
    Conditions
    1. Type 1 Diabetes
    Interventions
    1. Behavioral: DiaBetter Together
    2. Behavioral: Peer Mentor Delivery
    MeSH:Diabetes Mellitus Diabetes Mellitus, Type 1
    HPO:Diabetes mellitus Type I diabetes mellitus

    Primary Outcomes

    Description: HbA1c is the average blood glucose over 3-4 months. The American Diabetes Association recommends an HbA1c target of <7.0%. HbA1c is collected via fingerstick/blood assay at routine diabetes visits and will be extracted from the medical record at each clinic visit during the study period. At 12 months, HbA1c will be collected by at least one of the following methods: study visit at Texas Children's Hospital or Baylor College of Medicine to collect point of care HbA1c collection of most recent HbA1c from review of electronic medical chart (Texas Children's or Baylor College of Medicine) or medical records from outside provider (obtained with written permission from participant) If unable to attend study visit, a home Hemoglobin A1c kit (A1cNow SELFCHECK, PTS Diagnostics, NGSP-Certified) will be mailed to the participant to complete and return to the study team. Collected for young adult participants in both arms, not Peer Mentors.

    Measure: Glycemic Control (HbA1c)

    Time: Baseline through 12-Months Post-Randomization

    Secondary Outcomes

    Description: Time will start on the date of the last pediatric care visit (may differ from date of enrollment in study). The event of interest is the date of the first adult care visit. Participants who do not follow-up with an adult care provider within 12 months of the last pediatric visit will be censored for the event at the 12-month time point.Collected for young adult participants in both arms, not Peer Mentors.

    Measure: Time to First Adult Care Visit

    Time: 12-Month Post-Randomization

    Description: The Self-Care Inventory-Revised, Short Form (SCI-RSF) is a 9-item measure that asks respondents the frequency with which they completed diabetes self-management tasks in the past 1-2 months. Item responses range from (1) Never to (5) Always, higher scores = higher adherence. Collected for young adult participants in both arms (baseline, 6 mo, 12 mo) and Peer Mentors (pre- and post-involvement in study).

    Measure: Diabetes Self-Management/Adherence (Self-Care Inventory-Revised, Short Form)

    Time: Baseline, 6-Month Post-Randomization, & 12-Month Post-Randomization

    Description: The Type 1 Diabetes and Life (T1DAL) measure assesses diabetes-specific health-related quality of life. Participants will complete the T1DAL version for their age (Adolescent: 12-17, 23 items; Young Adult: 18-25, 27 items; Adult-1: 26-45, 27 items), which asks respondents to rate the degree to which each item is true about their everyday quality of life with diabetes. Items responses range from 1 (not at all true) to 5 (very true) and total and subscales scores are calculated from 1-100 (higher = better quality of life). Collected for young adult participants in both arms (baseline, 6 mo, 12 mo) and Peer Mentors (pre- and post-involvement in study).

    Measure: Health-Related Quality of Life (Type 1 Diabetes and Life)

    Time: Baseline, 6-Month Post-Randomization, & 12-Month Post-Randomization

    Description: The Diabetes Strengths and Resilience (DSTAR) measure assesses participants' self-perceptions about what they do well with diabetes (known as diabetes strengths). Participants will complete the Young Adult version of the DSTAR, which asks respondents to rate how often the items represent their experiences/perspectives about their diabetes strengths. Items responses range from 0 (never) to 4 (almost always) and are calculated for total and subscale scores (higher = more strengths). Collected for young adult participants in both arms, not Peer Mentors.

    Measure: Diabetes Strengths (Diabetes Strengths and Resilience measure)

    Time: Baseline, 6-Month Post-Randomization, & 12-Month Post-Randomization

    Description: The 2-Way Social Support Scale (2SSS) is a 20-item measure that assesses participants' experiences of giving and receiving social support. There are four scales: giving emotional support, giving instrumental support, receiving emotional support, and receiving instrumental support. Items responses range from 0 (not at all) to 5 (always) and are calculated for total and subscale scores (higher = more perceived support). Collected for young adult participants in both arms (Receiving scales only, 10 items: baseline, 6 mo, 12 mo) and Peer Mentors (Receiving and Giving scales, 20 items: pre- and post-involvement in study).

    Measure: Social Support (2-Way Social Support Scale)

    Time: Baseline, 6-Month Post-Randomization, & 12-Month Post-Randomization

    Description: The Diabetes Distress Scale for Adults with T1D (DDS-T1D) is a 28-item self-report scale that measures participants' experiences with distress related to living with diabetes. It assesses seven dimensions of distress: powerlessness, management distress, hypoglycemia distress, negative social perceptions, eating distress, physician distress, and friends/family distress. Items responses range from 1 (not a problem) to 6 (a very serious problem) and are calculated for total and subscale scores (higher = more distress). Collected for young adult participants in both arms (baseline, 6 mo, 12 mo) and Peer Mentors (pre- and post-involvement in study).

    Measure: Diabetes Distress (Diabetes Distress Scale for Adults with T1D)

    Time: Baseline, 6-Month Post-Randomization, & 12-Month Post-Randomization

    Description: The PROMIS Short Form Depression 4a consists of 4 items that are pulled from the PROMIS Depression Item Bank v1.0. These items assess how often the individual has been bothered by depression-related symptoms, including negative mood (sadness, guilt), views of self (self-criticism, worthlessness), and social cognition (loneliness, interpersonal alienation), and decreased positive affect and engagement (loss of interest, meaning, and purpose), over the last 7 days. Items responses range from 1 (never) to 6 (always) and are calculated into a total score (higher = more depressive symptoms). Collected for young adult participants in both arms, not Peer Mentors.

    Measure: Depressive Symptoms (PROMIS Short Form Depression 4a)

    Time: Baseline, 6-Month Post-Randomization, & 12-Month Post-Randomization

    Description: The PROMIS Short Form Emotional Support 4a assesses perceived feelings of being cared for and valued as a person and having supportive relationships. Participants respond to 4 items on a scale from 1(Never) to 5 (Always) and are calculated into a total score (higher = more perceived support). Collected for young adult participants in both arms, not Peer Mentors.

    Measure: Emotional Support (PROMIS Short Form Emotional Support 4a)

    Time: Baseline, 6-Month Post-Randomization, & 12-Month Post-Randomization

    Description: The PROMIS Short Form Informational Support 4a assesses perceptions about the information or resources others provide to them (adequacy, availability, helpfulness). Participants respond to 4 items on a scale from 1(Never) to 5 (Always) and are calculated into a total score (higher = more perceived support). Collected for young adult participants in both arms, not Peer Mentors.

    Measure: Informational Support (PROMIS Short Form Informational Support 4a)

    Time: Baseline, 6-Month Post-Randomization, & 12-Month Post-Randomization

    Description: The PROMIS Short Form Social Isolation 4a assesses participants' feelings of being isolated from other people. There is no time frame for responding to this measure. Participants respond to 4 items on a scale from 1(Never) to 5 (Always) and are calculated into a total score (higher = more perceived isolation). Collected for young adult participants in both arms, not Peer Mentors.

    Measure: Social Isolation (PROMIS Short Form Social Isolation 4a)

    Time: Baseline, 6-Month Post-Randomization, & 12-Month Post-Randomization

    Description: The Readiness Assessment of Emerging Adults With Type 1 Diabetes Diagnosed in Youth (READDY) is a 46-item self-report scale that measures participants' preparation for the transition to adult diabetes care, including: knowledge of diabetes, navigation of diabetes care, management skills and behaviors, and insulin pump skills if applicable. Only the Knowledge (12 items - baseline and 12 mos only), Navigation (13 items, baseline, 6 and 12 mos), Health Behaviors (9 items, baseline and 12 mos only) scales will be administered for this study. Items responses range from 0 (haven't thought about it) to 5 (yes, i can do this) and are calculated for a total score (higher = more ready). Collected for young adult participants in both arms, not Peer Mentors.

    Measure: Transition Readiness (Readiness Assessment of Emerging Adults With Type 1 Diabetes Diagnosed in Youth)

    Time: Baseline, 6-Month Post-Randomization, & 12-Month Post-Randomization

    Description: The Satisfaction with Life Scale (SWLS) is a 5-item self-report scale that measures participants' perceptions about their life overall. Items responses range from 1 (strongly disagree) to 7 (strongly agree) and are calculated for a total score (higher = better quality of life). Collected for young adult participants in both arms, not Peer Mentors.

    Measure: General Quality of Life (Satisfaction with Life Scale)

    Time: Baseline, 6-Month Post-Randomization, & 12-Month Post-Randomization
    3 "Coronavirus SARS-CoV2 and Diabetes Outcomes" : CORONADO

    COVID-19 (Coronavirus Disease-2019) is a life-threatening infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that appeared in December 2019 in the Wuhan district. COVID-19 has since affected more than 150 countries across the world and especially France. The first epidemiological data, mostly from Chinese studies, indicate that diabetes is one of the most common comorbidities, with high blood pressure, in patients with COVID-19. Moreover, the presence of diabetes at admission would be a risk factor for both ICU hospitalization and death. Nevertheless, specific data on people with diabetes and COVID-19 are fragmentary, justifying the achievement of a dedicated prospective observational study. The French nationwide CORONADO study aims to specifically describe the phenotypic characteristics of patients with diabetes admitted to hospital with COVID-19 infection. Particular attention will be devoted to glycemic control at admission (i.e. the level of HbA1c), the diabetic complications, as well as anti-diabetic and antihypertensive therapies. This study will provide answers to caregivers and patients with diabetes regarding the risk factors related to diabetes for COVID-19 prognosis. This pilot study will be used for the development of new studies and for the establishment of recommendations for the cost of care in patients with diabetes and COVID-19.

    NCT04324736
    Conditions
    1. Coronavirus
    2. Diabetes
    Interventions
    1. Other: no interventional study
    MeSH:Coronavirus Infections Diabetes Mellitus
    HPO:Diabetes mellitus

    Primary Outcomes

    Description: Prevalence of severe forms among all COVID-19 patients with diabetes

    Measure: Assess the prevalence of severe forms among hospitalized patients with diabètes and COVID-19

    Time: 1 month

    Secondary Outcomes

    Description: Use the body weight, type of diabetes, tglycemic control (HbA1C at admission), the comorbidities and complications associated with diabetes and finally the usual therapies.

    Measure: describe the clinical and biological characteristics of hospitalized subjects with diabetes and COVID-19

    Time: 1 month

    Description: death at 7 days after admission, hospital death and date of death, total length of hospitalization and discharge procedures, serious form requiring the use of artificial ventilation with tracheal intubation and date of use of this treatment, decision to limit

    Measure: describe the prognosis of hospitalized subjects with diabetes and COVID-19

    Time: 1 month

    Description: care service where the patient is taken care of, insulin therapy (IVSE or multi-injection) and dose of insulin required on D2 and D7

    Measure: describe the care management of hospitalized subjects with diabetes and COVID-19

    Time: 1 month
    4 Impact of Tele-Interventions During the COVID-19 Pandemic on Glycemic Control and Attitude Toward the Disease in Patients With Diabetes Mellitus - A Randomized Clinical Trial

    INTRODUCTION In critical situations, such as the current COVID 19 pandemic, themes of fear, uncertainty and stigmatization are common and constitute barriers to appropriate medical and mental health interventions. These challenges, when faced by those who live with a chronic disease, such as diabetes mellitus (DM), can negatively influence quality of life and adherence to treatment, compromising the control of the disease. OBJECTIVES The present study aims to investigate the effectiveness of a tele-intervention during the COVID-19 pandemic in improving glycemic control, lipid profile, blood pressure levels and parameters of medication adherence, mental well-being and sleep quality in patients with type 1 DM and type 2 DM. METHODS A randomized clinical trial will be carried out with patients with a previous diagnosis of type 1 DM and type 2 DM, who are registered at the Hospital de Clínicas de Porto Alegre (HCPA). Inclusion criteria will be age greater than or equal to 18 years, collection of HbA1c in the HCPA laboratory in January, February or March 2020 and availability to receive weekly phone calls. Patients will be randomized, stratified by type of diabetes, in two groups: G1: participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the social distancing period ; G2: participants will receive the usual care. The primary outcome assessed will be the variation in HbA1c levels comparatively between groups, with or without a tele-guided strategy, after four months of social distancing (or as long as the recommendation of social distancing measures remains). Secondary outcomes will include experiencing confirmation of COVID-19 infection, variation in lipid profile, blood pressure levels and variation in parameters of emotional distress related to diabetes, eating disorders, medication adherence, symptoms minor psychiatric disorders and altered sleep patterns, which will be evaluated with specific and validated scales. According to the sample calculation, 150 patients will be included in the study (92 with type 2 DM and 58 with type 1 DM). Analysis by intention to treat will be performed separately for patients with type 1 DM and with type 2 DM. SCHEDULE The proposed experiment will start immediately after approval of this project by the research ethics committee. The duration of the proposed intervention is 4 months (or as long as the recommendation of social distancing measures remains. This means that the study may be completed before or after that period, based on national recommendations for social distancing in Brazil), with a data analysis plan and publication of the results until September 2020.

    NCT04344210
    Conditions
    1. COVID
    2. Diabetes Mellitus, Type 2
    3. Diabetes Mellitus, Type 1
    Interventions
    1. Behavioral: Tele-interventions related to diabetes management and mental well-being
    MeSH:Diabetes Mellitus Diabetes Mellitus, Type 2 Diabetes Mellitus, Type 1
    HPO:Diabetes mellitus Type I diabetes mellitus Type II diabetes mellitus

    Primary Outcomes

    Description: Variation in HbA1c levels comparatively between groups after the period of social distancing measures.

    Measure: Variation in HbA1c levels

    Time: 4 months (or as long as the recommendation of social distancing measures remains)

    Secondary Outcomes

    Description: Confirmation of coronavirus infection by rapid test

    Measure: COVID-19 infection

    Time: 4 months (or as long as the recommendation of social distancing measures remains)

    Description: Comparison of the lipid profile of the last year with the lipid profile after the intervention between the groups.

    Measure: Variation in lipid profile

    Time: 4 months (or as long as the recommendation of social distancing measures remains)

    Description: Comparison of the blood pressure level of the last consultation with the pressure after the intervention between the groups.

    Measure: Variation in blood pressure levels

    Time: 4 months (or as long as the recommendation of social distancing measures remains)

    Description: Evaluation of emotional distress associated with the routine of living with diabetes - B-PAID (Brazilian Problem Areas In Diabetes Scale)

    Measure: Comparison of emotional distress associated with the routine of living with diabetes after intervention between groups

    Time: 4 months (or as long as the recommendation of social distancing measures remains)

    Description: Evaluation of eating disorders - EAT - 26 SCALE (Teste de Atitudes Alimentares)

    Measure: Comparison of eating disorders between groups

    Time: 4 months (or as long as the recommendation of social distancing measures remains)

    Description: Evaluation of adherence to the proposed clinical treatment - SCI R (Self-Care Inventory - revised)

    Measure: Comparison of adherence to the proposed clinical treatment between groups

    Time: 4 months (or as long as the recommendation of social distancing measures remains)

    Description: Evaluation of minor psychiatric disorders - SRQ 20 (Self Report Questionnaire)

    Measure: Comparison of minor psychiatric disorders between groups

    Time: 4 months (or as long as the recommendation of social distancing measures remains)

    Description: Evaluation of sleep pattern changes - MSQ (Mini Sleep Questionnaire)

    Measure: Comparison of sleep pattern changes between groups

    Time: 4 months (or as long as the recommendation of social distancing measures remains)
    5 Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19

    The coronavirus disease 2019 (COVID-19) is an emerging pandemic in 2020 caused by a novel coronavirus named SARS-CoV2. Diabetes confers a significant additional risk for COVID-19 patients. Dipeptidyl peptidase 4 (DPP-4) is a transmembrane glycoprotein expressed ubiquitously in many tissues. In addition to its effect on glucose levels, DPP-4 has various effects on the immune system and several diseases, including lung diseases. This trial aims to assess the safety and efficacy of linagliptin, a DPP-4 inhibitor, in the treatment of COVID-19. The trial will be randomized without blinding, with one are treated by insulin only for glucose balance and the other by insulin and linagliptin. The trial will assess the effects of linagliptin on different measures of COVID-19 recovery.

    NCT04371978
    Conditions
    1. COVID 19
    2. Coronavirus
    3. Diabetes Mellitus, Type 2
    4. Diabetes Mellitus
    5. Glucose Metabolism Disorders
    6. Metabolic Disease
    7. Endocrine System Diseases
    8. Dipeptidyl-Peptidase IV Inhibitors
    9. Linagliptin
    10. Severe Acute Respiratory Syndrome Coronavirus 2
    11. Sars-CoV2
    12. Hypoglycemic Agents
    13. Respiratory Tract Diseases
    14. Incretins
    15. Hormones
    Interventions
    1. Drug: Linagliptin 5 MG
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Respiratory Tract Diseases Diabetes Mellitus Diabetes Mellitus, Type 2 Metabolic Diseases Glucose Metabolism Disorders Endocrine System Diseases
    HPO:Abnormality of the endocrine system Diabetes mellitus Type II diabetes mellitus

    Primary Outcomes

    Description: Clinical change is defined as 2 points reduction in the World Health Organization (WHO) Ordinal Scale for Clinical Improvement of COVID-19: 0 - No clinical or virological evidence of infection; 1 - No limitation of activities; 2 - Limitation of activities; 3 - Hospitalized, no oxygen therapy; 4 - Oxygen by mask or nasal prongs; 5 - Non-invasive ventilation or high-flow oxygen; 6 - Intubation and mechanical ventilation; 7 - Ventilation + additional organ support - pressors, renal replacement therapy, extracorporeal membrane oxygenation; 8 - Death.

    Measure: Time to clinical change

    Time: 28 days

    Secondary Outcomes

    Measure: Percent of serious adverse events and premature discontinuation of treatment.

    Time: 28 days

    Description: Percent of patients with a 2 points reduction in the World Health Organization (WHO) Ordinal Scale for Clinical Improvement of COVID-19.

    Measure: Percent of patients with clinical improvement.

    Time: 28 days

    Measure: Length of hospitalization.

    Time: 28 days

    Measure: All-cause mortality.

    Time: 28 days

    Measure: Percent of supplemental oxygen use.

    Time: 28 days

    Measure: Supplemental oxygen-free days.

    Time: 28 days

    Measure: Percent of mechanical ventilation use.

    Time: 28 days

    Measure: Ventilator-free days.

    Time: 28 days

    Measure: Percent of ICU admissions.

    Time: 28 days

    Measure: ICU-free days.

    Time: 28 days

    Measure: Percent of 50% decrease in C-reactive protein (CRP) levels

    Time: Up to 28 days

    Measure: Time to virologic response, defined as no detection of SARS-CoV-2 in a PCR test.

    Time: 28 days
    6 Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients in Teodoro Maldonado Carbo Specialty's Hospital Infected and Diagnosed by SARS-Cov-2 With COVID-19

    This is a two-arm, open-label, randomized, phase 2, controlled center study to assess the safety and efficacy of Viusid and Asbrip in patients with mild to moderate symptoms of respiratory disease caused by 2019 coronavirus infection. Patients will be randomized to receive daily doses of 30 ml of Viusid and 10 ml of Asbrip every 8 hours or standard care. Viusid and Asbrip will be administered orally. A total of 60 subjects will be randomized 2: 1 in this study. 40 patients will be assigned to Viusid plus Asbrip plus standard of care and 20 control patients with standard of care. Treatment duration: 21 days.

    NCT04407182
    Conditions
    1. Covid-19
    2. Sars-CoV2
    3. Diabete Mellitus
    4. Cardiopathy
    5. Pulmonary Disease
    6. Renal Disease
    7. Liver Diseases
    Interventions
    1. Dietary Supplement: Viusid and Asbrip
    MeSH:Liver Diseases Diabetes Mellitus
    HPO:Abnormality of the liver Decreased liver function Diabetes mellitus Elevated hepatic transaminase

    Primary Outcomes

    Description: The number of days required to achieve a score of 0 for each symptom category. Resolution of symptoms: fever (time frame: 21 days) Fever based on a 0-3 scale: 0 = ≤98.6, 1 => 98.6- 100.6, 2 => 100.6 - 102.6, 3 => 102.6 Resolution of symptoms: cough (time frame: 21 days) Cough based on a 0-3 scale: 0 = no cough, 1 = mild, 2 = moderate, 3 = severe Resolution of symptoms: shortness of breath (time frame: 21 days) Shortness of breath based on a 0-3 scale: 0 = no shortness of breath, 1 = with moderate intensity exercise 2 = walking on a flat surface 3 = shortness of breath when dressing or doing daily activities Resolution of symptoms: fatigue (period: 21 days) Fatigue based on a 0-3 scale: 1 = mild fatigue, 2 = moderate fatigue, 3 = severe fatigue. Composite score that includes all symptoms: (time frame: 21 days) Total composite score of symptoms on days 5, 10, 15, and 21 of study supplementation.

    Measure: Symptom resolution

    Time: 21 days

    Secondary Outcomes

    Description: Disease severity will be measured using a disease severity clinical event scale (assessed until day 21) Change from baseline in the patient's health status on an ordinal scale of 7 categories (time frame: days 3, 7, 14, 21) death Hospitalized, with invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) Hospitalized, with non-invasive ventilation or high-flow oxygen devices Hospitalized, requiring supplemental oxygen Hospitalized, which does not require supplemental oxygen Not hospitalized, limitation of activities. Not hospitalized, without limitations in activities. Note: lower scores mean a worse result.

    Measure: Cumulative incidence of disease severity

    Time: 21 days

    Description: Differences in the number of patients who received complementary medications for diagnosis between the study arms.

    Measure: Complementary drugs required

    Time: 21 days

    Description: Differences in the number of patients in the study groups experiencing side effects of the supplements.

    Measure: Side effects of supplementation

    Time: 21 days

    Description: PCR analysis at day 0, 7th, 14th and 21th to measure and compare viral load

    Measure: Duration of SARS-CoV-2 PCR positivity

    Time: 21 days

    Description: Blood biochemical analysis at day 0, 3rd, 7th, 14th and 21th

    Measure: Concentration of reactive protein c in peripheral blood

    Time: 21 days

    Description: Number of Incidence of hospitalization

    Measure: Incidence of hospitalization

    Time: 21 days

    Description: Number of days of hospitalization

    Measure: Duration (days) of hospitalization

    Time: 21 days

    Description: Number of Incidences of mechanical ventilation supply per patient

    Measure: Incidence of mechanical ventilation supply

    Time: 21 days

    Description: Number of days with mechanical ventilation supply

    Measure: Duration (days) of mechanical ventilation supply

    Time: 21 days

    Description: Number of incidences of oxygen use

    Measure: Incidence of oxygen use

    Time: 21 days

    Description: Number of days of oxygen use per patient

    Measure: Duration (days) of oxygen use

    Time: 21 days

    Description: Number of death per group

    Measure: Mortality rate

    Time: 21 days

    Description: Number of days patient need to recover from disease

    Measure: Time to return to normal activity

    Time: 21 days

    Other Outcomes

    Description: Change from baseline in serum cytokine IL-1 level by blood biochemical analysis at day 0, 3, 7, 14 and 21

    Measure: Change from baseline in serum cytokine levels

    Time: 21 days

    Description: Change from baseline in serum cytokine IL-6 level by blood biochemical analysis at day 0, 3, 7, 14 and 21

    Measure: Change from baseline in serum cytokine levels

    Time: 21 days

    Description: Change from baseline in serum cytokine TNF-α level by blood biochemical analysis at day 0, 3, 7, 14 and 21

    Measure: Change from baseline in serum cytokine levels

    Time: 21 days

    Description: Change from baseline in CCR5 receptor occupancy levels for Tregs and macrophages by blood biochemical analysis at day 0, 3, 7, 14 and 21

    Measure: Change from baseline in CCR5 receptor occupancy levels for Tregs and macrophages

    Time: 21 days

    Description: Change from baseline in CD3 +, CD4 + and CD8 + T cell counts by blood biochemical analysis at day 0, 3, 7, 14 and 21.

    Measure: Change from baseline in CD3 +, CD4 + and CD8 + T cell counts

    Time: 21 days

    Description: Change in liver function test (AST, ALT and TBIL) by blood biochemical analysis at day 0, 4, 7, 14 and 21.

    Measure: Change in liver function test

    Time: 21 days

    Description: Change in kidney function with eGFR rate by blood and urinary biochemical analysis at day 0, 4, 7, 14 and 21.

    Measure: Change in kidney function test

    Time: 21 days

    Description: Change in kidney function with creatine clearance rate by blood and urinary biochemical analysis at day 0, 4, 7, 14 and 21.

    Measure: Change in kidney function test

    Time: 21 days

    Description: Change in routine blood test red blood cells concentration by blood biochemical analysis at day 0, 4, 7, 14 and 21.

    Measure: Change in routine blood test

    Time: 21 days

    Description: Change in routine blood test white blood cell concentration by blood biochemical analysis at day 0, 4, 7, 14 and 21.

    Measure: Change in routine blood test

    Time: 21 days

    Description: Change in routine blood test D-dimer level by blood biochemical analysis at day 0, 4, 7, 14 and 21.

    Measure: Change in routine blood test

    Time: 21 days

    Description: Change in routine blood test fibrinogen level by blood biochemical analysis at day 0, 4, 7, 14 and 21.

    Measure: Change in routine blood test

    Time: 21 days

    Description: Change in myocardial enzyme CPK-MB by blood biochemical analysis at daty 0, 4, 7, 14 and 21

    Measure: Change in myocardial enzymes

    Time: 21 days

    Description: Change in myocardial enzymes troponins by blood biochemical analysis at daty 0, 4, 7, 14 and 21

    Measure: Change in myocardial enzymes

    Time: 21 days
    7 Glycaemia and Cardiac Function in Patients With COVID-19

    The study design is observational, exploratory study consisting of two cohorts of COVID-19 patients admitted to the ICU and the medical ward, respectively. The primary outcome focusing on the effect of plasma glucose levels on cardiac function will be evaluated by repeated assessment of cardiac function by echocardiography and measurement of plasma glucose. Furthermore, blood coagulability will be evaluated to determine the importance of diabetes status and plasma glucose changes for whole blood coagulability at time of admission to the ICU and progression in coagulability abnormalities. In the medical ward cohort, two assessments will be performed separated by no more than 12 hours. In the ICU cohort, three assessments will be performed separated by no more than 6 hours. Ideally, 60 patients with COVID-19 will be included in the ICU cohort with a 1:1 distribution between patient with and without diabetes. Ideally, 40 patients with diabetes will be included in the cohort of patients admitted to medical ward (hospitalisation cohort). The primary hypothesis is that levels of plasma glucose have clinically significant impact on left ventricular systolic function in patients with COVID-19 admitted to the ICU. The secondary hypothesis is that the impact of plasma glucose on left ventricular systolic function is associated with glycaemic control prior to admission as measured by HbA1c.

    NCT04410718
    Conditions
    1. Diabetes Mellitus
    2. Diabetes Mellitus, Type 2
    3. Diabetes Mellitus, Type 1
    4. COVID
    Interventions
    1. Other: Glycaemic levels
    MeSH:Diabetes Mellitus Diabetes Mellitus, Type 2 Diabetes Mellitus, Type 1
    HPO:Diabetes mellitus Type I diabetes mellitus Type II diabetes mellitus

    Primary Outcomes

    Description: The within-subject effect of plasma glucose levels on left ventricular systolic function as measured by left ventricular ejection fraction (a pooled analysis of the hospitalisation cohort and ICU cohort)

    Measure: Plasma glucose levels and left ventricular ejection fraction

    Time: The study applies a mixed model for assessment of within-subject effects by repeated assessment in same individual. The time frame is from first assessment until last assessment (max. 24 hours).

    Secondary Outcomes

    Description: Difference in the within-subject effect of plasma glucose levels on left ventricular systolic function as measured by left ventricular ejection fraction between patients with chronic hyperglycaemia prior to admission (HbA1c >53 mmol/mol) and with normoglycaemia prior to admission (HbA1c ≤53 mmol/l) (ICU cohort only)

    Measure: Key secondary outcome: HbA1c, plasma glucose levels and left ventricular systolic function

    Time: The study applies a mixed model for assessment of within-subject effects by repeated assessment in same individual. The time frame is from first assessment until last assessment (max. 24 hours).

    Description: The within-subject effect of plasma glucose levels on left ventricular systolic function as measured by strain analysis (a pooled analysis of the hospitalisation cohort and ICU cohort)

    Measure: Plasma glucose levels and strain analysis

    Time: The study applies a mixed model for assessment of within-subject effects by repeated assessment in same individual. The time frame is from first assessment until last assessment (max. 24 hours).

    Description: The within-subject effect of plasma glucose levels on left ventricular systolic function as measured by mitral annular systolic velocity (a pooled analysis of the hospitalisation cohort and ICU cohort)

    Measure: Plasma glucose levels and mitral annular systolic velocity

    Time: The study applies a mixed model for assessment of within-subject effects by repeated assessment in same individual. The time frame is from first assessment until last assessment (max. 24 hours).

    Description: Differences in the within-subject effect of plasma glucose levels on left ventricular systolic function as measured by left ventricular ejection fraction between the hospitalisation cohort, the ICU cohort with diabetes and the ICU cohort without diabetes, respectively

    Measure: Plasma glucose levels and left ventricular ejection fraction (sub-group analysis)

    Time: The study applies a mixed model for assessment of within-subject effects by repeated assessment in same individual. The time frame is from first assessment until last assessment (max. 24 hours).

    Description: Differences in the within-subject effect of plasma glucose levels on left ventricular systolic function as measured by strain analysis between the hospitalisation cohort, the ICU cohort with diabetes and the ICU cohort without diabetes, respectively

    Measure: Plasma glucose levels and strain analysis (sub-group analysis)

    Time: The study applies a mixed model for assessment of within-subject effects by repeated assessment in same individual. The time frame is from first assessment until last assessment (max. 24 hours).

    Description: Differences in the within-subject effect of plasma glucose levels on left ventricular systolic function as measured by mitral annular systolic velocity between the hospitalisation cohort, the ICU cohort with diabetes and the ICU cohort without diabetes, respectively

    Measure: Plasma glucose levels and mitral annular systolic velocity (sub-group analysis)

    Time: The study applies a mixed model for assessment of within-subject effects by repeated assessment in same individual. The time frame is from first assessment until last assessment (max. 24 hours).

    Description: Difference in the within-subject effect of plasma glucose levels on left ventricular systolic function as measured by strain analysis between patients with chronic hyperglycaemia prior to admission (HbA1c >53 mmol/mol) and with normoglycaemia prior to admission (HbA1c ≤53 mmol/l) (ICU cohort only)

    Measure: HbA1c, Plasma glucose levels and strain analysis

    Time: The study applies a mixed model for assessment of within-subject effects by repeated assessment in same individual. The time frame is from first assessment until last assessment (max. 24 hours).

    Description: Difference in the within-subject effect of plasma glucose levels on left ventricular systolic function as measured by mitral annular systolic velocity between patients with chronic hyperglycaemia prior to admission (HbA1c >53 mmol/mol) and with normoglycaemia prior to admission (HbA1c ≤53 mmol/l) (ICU cohort only)

    Measure: HbA1c, Plasma glucose levels and mitral annular systolic velocity

    Time: The study applies a mixed model for assessment of within-subject effects by repeated assessment in same individual. The time frame is from first assessment until last assessment (max. 24 hours).

    Description: Difference in whole blood coagulability and fibrinolysis as measured by TEG between patients with and without diabetes at time of admission to the ICU (ICU cohort only)

    Measure: Diabetes status and whole blood coagulability and fibrinolysis

    Time: At time of admission to the ICU (max. 24 hours after admission to the ICU)

    Description: Difference in change in whole blood coagulability and fibrinolysis as measured by TEG between patients with and without diabetes treated at the ICU (ICU cohort only)

    Measure: Diabetes status and change in whole blood coagulability and fibrinolysis during ICU stay

    Time: From first until last assessment during ICU stay (max. 24 hours).

    Description: The prognostic value of cardiac function and TEG on the following patient outcomes 1) need for treatment in the ICU (hospitalisation cohort only) 2) need for respirator treatment (hospitalisation cohort only) 3) COVID-19 related death

    Measure: Prognostic value of TEG analysis

    Time: From time of admission and until four weeks after admission

    Description: The prognostic value of cardiac function on the following patient outcomes 1) need for treatment in the ICU (hospitalisation cohort only) 2) need for respirator treatment (hospitalisation cohort only) 3) COVID-19 related death

    Measure: Prognostic value of cardiac function

    Time: From time of admission and until four weeks after admission

    Description: Difference in cardiac damage as measured by high-sensitivity troponin (hs-troponin) between patients with and without diabetes admitted to the ICU (ICU cohort only)

    Measure: Diabetes status and high-sensitivity troponins

    Time: At the time of admission to the ICU (max. 24 hours after admission to the ICU)

    Description: Difference in change in cardiac damage as measured by high-sensitivity troponin (hs-troponin) between patients with and without diabetes admitted to the ICU (ICU cohort only)

    Measure: Diabetes status and change high-sensitivity troponins

    Time: From first until last assessment during ICU stay (max. 24 hours)
    8 Prevalence of Diabetes Among Hospitalized Patients With Covid-19 in West of Algeria. Identification of Diabetes-related Associated Factors Severe Forms

    By Jan 7, 2020, Chinese scientists had isolated a novel coronavirus, from patients with virus-infected pneumonia. The WHO designated later this virus as COVID-19 (coronavirus disease 2019). This exponential pandemic coronavirus infection is responsible for severe forms in 15 to 20%, for critical ill requiring ventilation in 5% and for mortality in 2%. Algeria was part of the 13 top priority countries identified by WHO based on their direct links and volume of travel to the infected provinces in China. It is known that some predisposing conditions lead to a worse outcome with coronavirus. In China, the overall case-fatality rate was 2.3%, but was higher in patients with diabetes (7.3%). In Italy, the most common comorbidities associated with death from COVID-19 were hypertension (73.8%) and diabetes (33.9%). The US Centers for Disease Control and Prevention suggests diabetes is the most common comorbidity in COVID-19 cases. In the largest cohort NHS England study, death from COVID-19 was strongly associated with uncontrolled diabetes (after full adjustment, HR 2.36). The West Algerian CORODIAB-13 study aims is (1) to assess the prevalence of diabetes among hospitalized patients with Covid-19, (2) to describe the phenotypic characteristics of patients with diabetes, and (3) to identify the parameters specific to the diabetic which are associated with severe forms. In the future, this study will provide answers for two main questions 1. Why diabetics are more at risk of developing Covid-19 infection? 2. Why diabetics are at high risk of developing severe forms?

    NCT04412746
    Conditions
    1. Coronavirus Infections
    2. Diabetes Mellitus
    3. Prevalence
    4. Risk Factors
    5. Patient Outcome Assessment
    6. Severe Acute Respiratory Syndrome
    Interventions
    1. Drug: MANAGEMENT OF COVID-19
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Diabetes Mellitus
    HPO:Diabetes mellitus

    Primary Outcomes

    Description: Assess the prevalence of diabetes among hospitalized patients with Covid-19 in Area of Tlemcen

    Measure: Prevalence of diabetes among all hospitalized COVID-19

    Time: 3 months

    Description: Describe the clinical and biological characteristics of hospitalized subjects with diabetes and COVID-19

    Measure: Diabetes-related factors risk

    Time: 3 months
    9 Remote Glucose Monitoring of Patients With Diabetes Quarantined During the COVID-19 Pandemic - a Hospital-Based Randomized Controlled Trial of the Effect of Remote Continuous Glucose Monitoring Compared to Usual Glucose Monitoring

    This is a randomized controlled trial of isolated patients with diabetes admitted to Nordsjællands Hospital with or without COVID-19-pneumonia. A continuous glucose monitoring (CGM) based system with transmission of glucose data to a central system is used for remote monitoring of glucose levels and compared to standard finger-prick glucose. Blinded (to patients) CGM is mounted in the finger-prick group.

    NCT04430608
    Conditions
    1. Diabetes
    2. Covid-19
    3. Infection
    Interventions
    1. Device: Dexcom G6
    MeSH:Diabetes Mellitus
    HPO:Diabetes mellitus

    Primary Outcomes

    Description: TIR is presented in percent of time in which the participants' glucose values are in different glucose ranges.

    Measure: Time In Range (TIR) for blood glucose

    Time: 1-2 weeks

    Secondary Outcomes

    Description: Saved patient-personnel contacts related to blood glucose measurements, incl. time healthcare providers spent on diabetes related tasks and PPE related tasks, during the patients' hospitalization.

    Measure: Saved patient-personnel contacts related to blood glucose measurements.

    Time: 1-2 weeks

    Description: Additional glucose outcomes based on data from Dexcom G6 are for example Time Above Range (TAR), Time Below Range (TBR), average glucose, variance in glucose (CV), etc.

    Measure: Glucose variations during hospitalization

    Time: 1-2 weeks

    Description: That is: Tablet-based and insulin-based regimens and number of times that sliding scale insulin (including dose of insulin) has been administered for each patient.

    Measure: Blood glucose lowering interventions

    Time: 1-2 weeks

    Description: Number of techincal errors during the sensors lifetime.

    Measure: CGM sensor performance

    Time: 1-2 weeks

    Description: Hospital death (yes/no), length of stay at hospital, need for respiratory support (yes/no) and intensive care (yes/no), recovered vs. fatal (death within 60 days from admission).

    Measure: Course of hospital stay.

    Time: 1-2 weeks
    10 Assessing the Impact of the COVID-19 Lockdown on Metabolic Control and Access to Health Care in Patients With Diabetes: a Monocentric Cross-sectional Study

    The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the COVID-19 (Coronavirus Disease-2019) in December 2019 has led to an unprecedented international health situation. Exceptional measures have been taken by public authorities worldwide in order to slow the spread of the virus and prevent healthcare systems from becoming overloaded. In France, a national lockdown has been established during approximately 2 months to increase social distancing and restrict population movements. Hospital routine care appointments have been cancelled, in order to reallocate medical resources towards COVID-19 units and limit contacts between patients within hospitals or waiting rooms. While the virus itself, the disease and potential treatments are currently extensively studied, little data are available on the effect of these public health decisions on the management of a chronic condition such as diabetes. The French regional CONFI-DIAB study aims at assessing the collateral impact of routine care cancellation during the national lockdown due to COVID-19 in patients with a chronic condition such as diabetes. Special attention will be given to metabolic control and access to health care. This cross-sectional study should provide information on the consequences of a global lockdown and the associated routine care cancellation on the management of diabetes, and inform future decision making in the event of a new pandemic.

    NCT04485351
    Conditions
    1. Diabetes Mellitus
    2. Coronavirus Infection
    3. Metabolic Disease
    4. Glucose Metabolism Disorders
    Interventions
    1. Other: no intervention
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Diabetes Mellitus Metabolic Diseases Glucose Metabolism Disorders
    HPO:Diabetes mellitus

    Primary Outcomes

    Description: HbA1c levels before and after the lockdown period. A 3 months period is required between the 2 values.

    Measure: Compare glycated hemoglobin levels of patients with diabetes from the University Hospital of Nancy between the period preceding and following the lockdown related to the COVID-19 pandemic.

    Time: 6 months period prior to lockdown - 6 weeks period following the end of the lockdown

    Secondary Outcomes

    Description: Use type of diabetes, BMI, lipid profile, micro- and macro-comorbidities and usual therapies from medical records

    Measure: Describe the clinical and biological characteristics of patients with diabetes followed in routine care at the University Hospital of Nancy

    Time: 6 weeks period following the end of the lockdown

    Description: Use BMI, lipid profile, renal and hepatic function from medical records

    Measure: Describe the change from baseline of biological and clinical parameters of patients with diabetes followed in routine care at the University Hospital of Nancy between the period preceding and following the lockdown.

    Time: 6 months period prior to lockdown - 6 weeks period following the end of the lockdown

    Description: Ketosis, Ketoacidosis, severe hypoglycemia, COVID-19 infection, hospitalization

    Measure: Describe the proportion of patients who presented with one or more significant clinical event during the lockdown.

    Time: 6 weeks period following the end of the lockdown

    Description: Proportion of patients who forgot and/or discontinued one or several medication(s), medication involved, duration and frequency of omission/discontinuation

    Measure: Describe the proportion of patients who forgot and/or discontinued one or several medication(s) during the lockdown.

    Time: 6 weeks period following the end of the lockdown

    Description: Porportion of patients who modified their usual level of physical activity and/or their consumption of alcohol and/or tobacco

    Measure: Describe the proportion of patients who changed their lifestyle's habits during the lockdown.

    Time: 6 weeks period following the end of the lockdown

    Description: Proportion of patients who consulted their GP, a specialist physician, pharmacist, biologist, nurse, paramedic, other healthcare professional; type of visit (regular face to face, telemedecine); method for prescription renewal; reason for delay in care; hospitalization (excluding for COVID-19)

    Measure: Describe healthcare consumption of patients with diabetes during the lockdown.

    Time: 6 weeks period following the end of the lockdown

    Description: Proportion of patients who (1) was tested for SARS-CoV-2 by PCR, (2) developped COVID-19 confirmed by PCR and (3) was hospitalized due to the severity of COVID-19.

    Measure: Describe the proportion of patients who (1) was tested for SARS-CoV-2 by PCR, (2) developped COVID-19 confirmed by PCR and (3) was hospitalized due to the severity of COVID-19.

    Time: 6 weeks period following the end of the lockdown
    11 Determining the Impact of COVID-19 Lockdown on Metabolic Control in Individuals With Type 2 Diabetes

    The strict rules applied in Italy during the recent COVID-19 pandemic, with the prohibition to attend any regular outdoor activity, are likely to influence the degree of metabolic control of patients with type 2 diabetes. The aim of this observational, prospective, single centre study was to evaluate the immediate impact of the lockdown rules on the metabolic profile of a cohort of patients with type 2 diabetes.

    NCT04501991
    Conditions
    1. Type 2 Diabetes
    2. Metabolic Control
    Interventions
    1. Other: antidiabetic treatment
    MeSH:Diabetes Mellitus Diabetes Mellitus, Type 2
    HPO:Diabetes mellitus Type II diabetes mellitus

    Primary Outcomes

    Description: Blood glucose was expressed in mg/dl and was determined by standard techniques.

    Measure: Glucose

    Time: One week after the end of the lockdown period

    Description: HbA1c was expressed as percentage or mmol/l and was determined by standard techniques.

    Measure: HbA1c

    Time: One week after the end of the lockdown period

    Description: Complete lipid profile (total cholesterol, HDL cholesterol, LDL cholesterol, Triglcerydes) were expressed in mg/dl or mmol/l and were determined by standard techniques.

    Measure: Lipid profile

    Time: One week after the end of the lockdown period
    12 Canakinumab in Patients With COVID-19 and Type 2 Diabetes - CanCovDia Trial

    The purpose of this study is to evaluate whether Canakinumab has beneficial effects on patients with Type 2 diabetes mellitus and coronavirus disease 19 (COVID19).

    NCT04510493
    Conditions
    1. Coronavirus Infection
    2. Diabetes Mellitus, Type 2
    Interventions
    1. Drug: Canakinumab
    2. Drug: Placebo
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Diabetes Mellitus Diabetes Mellitus, Type 2
    HPO:Diabetes mellitus Type II diabetes mellitus

    Primary Outcomes

    Description: Treatment and placebo will be compared on the basis of the unmatched win-ratio approach of Pocock. When comparing two patients, the winner will be determined by the first component in which the two patients differ (4 weeks after randomization): longer survival time longer ventilation-free time longer ICU-free time shorter hospitalization time If there is no difference between treatment and Placebo: the win ratio is 1. If there is a difference between treatment and Placebo: the win ratio is not 1.

    Measure: unmatched win ratio after treatment with canakinumab compared to Placebo (composite endpoint)

    Time: within 4 weeks after treatment with canakinumab or placebo

    Secondary Outcomes

    Description: Time to clinical improvement, defined as the time from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever comes first. "The seven-category ordinal scale consists of the following categories: not hospitalized with resumption of normal activities; not hospitalized, but unable to resume normal activities; hospitalized, not requiring supplemental oxygen; hospitalized, requiring supplemental oxygen; hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and death"

    Measure: Time to clinical improvement

    Time: From randomization up to 4 weeks

    Description: Death rate during the 4-week period after study treatment

    Measure: Death rate

    Time: 4 weeks

    Description: Admission to the intensive care unit from the medical ward during the 4-week period after study treatment

    Measure: Admission to intensive care unit (ICU)

    Time: 4 weeks

    Description: Secondary worsening of disease (i.e., development of Acute respiratory distress Syndrome (ARDS), increase of oxygen demand after 72h of treatment)

    Measure: Secondary worsening of disease

    Time: 4 weeks

    Description: Prolonged hospital stay > 3 weeks

    Measure: Prolonged hospital stay

    Time: >3 weeks

    Description: Ratio to baseline in the glycated hemoglobin

    Measure: Change in ratio to baseline in the glycated hemoglobin

    Time: Baseline, Day 29 and Day 90

    Description: Ratio to baseline in the fasting glucose

    Measure: Change in ratio to baseline in the fasting glucose

    Time: Baseline, Day 29

    Description: Ratio to baseline in the fasting insulin

    Measure: Change in ratio to baseline in the fasting insulin

    Time: Baseline, Day 29

    Description: Ratio to baseline in the fasting c-peptide

    Measure: Change in ratio to baseline in the fasting c-peptide

    Time: Baseline, Day 29

    Description: Ratio to baseline in the C-reactive protein (CRP)

    Measure: Ratio to baseline in the C-reactive protein (CRP)

    Time: Baseline, Day 29 and Day 90

    Description: Ratio to baseline in the D-dimer

    Measure: Change in ratio to baseline in the D-dimer

    Time: Baseline, Day 29

    Description: Ratio to baseline in the Natriuretic peptide (NTproBNP)

    Measure: Change in ratio to baseline in the Natriuretic peptide (NTproBNP)

    Time: Baseline, Day 29 and Day 90

    Description: Ratio to baseline in the Glomerular Filtration Rate Renal (eGFR)

    Measure: Change in ratio to baseline in the Glomerular Filtration Rate Renal (eGFR)

    Time: Baseline, Day 29 and Day 90

    Description: Type of antidiabetic treatment at Day 29

    Measure: Type of antidiabetic treatment at Day 29

    Time: Day 29

    Description: Number of antidiabetic treatment at Day 29

    Measure: Number of antidiabetic treatment at Day 29

    Time: Day 29

    Description: Type of antidiabetic treatment at three months

    Measure: Type of antidiabetic treatment at three months

    Time: Month 3

    Description: Number of antidiabetic treatment at three months

    Measure: Number of antidiabetic treatment at three months

    Time: Month 3
    13 Glycemic Control Among Children and Adolescents With Type 1 Diabetes During COVID-19 Pandemic in Egypt: A Pilot Study

    During the current unusual situation with COVID-19 pandemic and the lockdown applied in most of the countries, school students were kept at home and offered e-learning modules and all activities were suspended. Lockdown entails significant modifications of life style, involving changes in physical activities, dietary habits and nutrition, which are likely to impact glycemic control. So the aim of the current study is to evaluate the impact of COVID-19 pandemic on glycemic control among children and adolescents with type 1 diabetes.

    NCT04531111
    Conditions
    1. Type 1 Diabetes
    2. Covid19
    MeSH:Diabetes Mellitus Diabetes Mellitus, Type 1
    HPO:Diabetes mellitus Type I diabetes mellitus

    Primary Outcomes

    Description: Change in HbA1c from baseline to 3 month after the lockdown

    Measure: Impact of COVID-19 pandemic and lockdown on glycemic control among a sample of Egyptian children and adolescents with type 1 diabetes

    Time: 12 weeks

    Secondary Outcomes

    Description: Change in total insulin dosage from baseline to 3 month after the lockdown

    Measure: Impact of COVID-19 pandemic and lockdown on insulin dosage among a sample of Egyptian children and adolescents with type 1 diabetes

    Time: 12 weeks
    14 Non-blinded, Randomized and Controlled Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19

    The treatment with pioglitazone added to the standard treatment of patients with DM2 hospitalized for COVID-19 may produce a decrease in the number of patients who progress to a second phase of severe systemic inflammation.

    NCT04535700
    Conditions
    1. Type 2 Diabetes
    Interventions
    1. Drug: Pioglitazone 30 mg
    2. Other: standard of care
    MeSH:Diabetes Mellitus Diabetes Mellitus, Type 2
    HPO:Diabetes mellitus Type II diabetes mellitus

    Primary Outcomes

    Description: Number of patients receive pioglitazone treatment during their hospital stay who receive support with mechanical ventilation, enter the ICU and / or die.

    Measure: Patients treated with pioglitazone, together with conventional treatment for COVID-19 infection, who during their admission evolve towards the need to receive support with mechanical ventilation, enter the ICU and / or die.

    Time: Through hospitalization period, an average of 10-20 days until hospital discharge

    Secondary Outcomes

    Description: Proportion of patients who develop heart failure or adverse reaction associated with treatment.

    Measure: Incidence of pioglitazone treatment-Emergent Adverse Events in patients with DM2 and symptomatic SARS-CoV-2 infection.

    Time: Everyday through hospitalization period, an average of 10-20 days until hospital discharge

    Description: Changes in this inflammation parameter: C-reactive protein (in mg/dl)

    Measure: Biomarker analysis: systemic inflammation parameters during the administration of pioglitazone treatment.

    Time: Each 48 hours through hospitalization period, an average of 10-20 days until hospital discharge

    Description: Changes in this inflammation parameter: D-dimer (in μg/mL)

    Measure: Biomarker analysis: systemic inflammation parameters during the administration of pioglitazone treatment.

    Time: Each 48 hours through hospitalization period, an average of 10-20 days until hospital discharge

    Description: Changes in this inflammation parameter: ferritin (in ng/mL)

    Measure: Biomarker analysis: systemic inflammation parameters during the administration of pioglitazone treatment.

    Time: Each 48 hours through hospitalization period, an average of 10-20 days until hospital discharge

    Description: Changes in this inflammation parameter: creatine kinase (CK) (in mg/dL)

    Measure: Biomarker analysis: systemic inflammation parameters during the administration of pioglitazone treatment.

    Time: Each 48 hours through hospitalization period, an average of 10-20 days until hospital discharge

    Description: Changes in this inflammation parameter: number of lymphocytes (in μL)

    Measure: Biomarker analysis: systemic inflammation parameters during the administration of pioglitazone treatment.

    Time: Each 48 hours through hospitalization period, an average of 10-20 days until hospital discharge
    15 Clinical Characteristics and Outcome of Hospitalized Children and Adolescent Patients With Type 1 Diabetes During the COVID-19 Pandemic: Data From a Single Center Surveillance Study in Egypt

    Although reports showed that children with well controlled diabetes do not appear to have increased risk of infection with SARS-CoV-2, however data are scarce regarding the extent to which clinical and demographic data of patient could modify the outcome and severity of the disease. Additionally, the link between covid-19 and diabetes remains controversial.

    NCT04536285
    Conditions
    1. Type 1 Diabetes
    2. Covid19
    MeSH:Diabetes Mellitus Diabetes Mellitus, Type 1
    HPO:Diabetes mellitus Type I diabetes mellitus

    Primary Outcomes

    Description: complications and comorbidities associated with diabetes

    Measure: Clinical characteristic of pediatric and adolescent patients with type 1 diabetes hospitalized with COVID -19.

    Time: 4 months

    Description: Acute phase reactants

    Measure: Laboratory characteristic of pediatric and adolescent patients with type 1 diabetes hospitalized with COVID -19.

    Time: 4 months

    Description: Intensive care admission

    Measure: Prognosis of pediatric and adolescent patients with type 1 diabetes hospitalized with COVID -19.

    Time: 4 month

    Secondary Outcomes

    Description: Incidence of new onset type 1 diabetes among confirmed cases of Covid-19 infection among children and adolescents

    Measure: Incidence of new onset type 1 diabetes among confirmed cases of Covid-19 infection among children and adolescents

    Time: 4 months

    Description: Impact of Covid-19 pandemic on presentation of diabetes and its acute complications among pediatric and adolescent patients with type 1 diabetes

    Measure: Presentation of diabetes and its acute complications among pediatric and adolescent patients with type 1 diabetes during COVID-19 Pandemic in Egypt

    Time: 4 month
    16 Clinical Phenotype and Outcomes of Inpatients With COVID-19 and Diabetes

    Patients with diabetes have been listed as people at higher risk for severe illness from COVID-19. Moreover, the relationship between diabetes-related phenotypes and the severity of COVID-19 remains unknown. This observational study aims to to evaluate the risk of disease severity and mortality in association with diabetes in COVID-19 inpatients and identify the clinical and biological features associated with worse outcomes.

    NCT04550403
    Conditions
    1. Diabetes Mellitus
    2. Covid19
    MeSH:Diabetes Mellitus
    HPO:Diabetes mellitus

    Primary Outcomes

    Description: to assess risk of intensive care unit admission and/or death among COVID-19 inpatients

    Measure: prevalence of intensive care unit admission and/or in-hospital mortality among COVID-19 inpatients

    Time: february 23 to march 31, 2020

    Secondary Outcomes

    Description: to compare risk of death among inpatients in presence or absence of diabetes

    Measure: prevalence of death among COVID-19 inpatients with and without diabetes

    Time: february 23 to march 31, 2020

    Description: to compare intensive care unit admission among inpatients in presence or absence of diabetes

    Measure: prevalence of intensive care unit admission among COVID-19 inpatients with and without diabetes

    Time: february 23 to march 31, 2020

    Description: to identify socio-demographic as predictors of severe prognosis (death or intensive care unit admission) during hospitalization

    Measure: demographic and clinical characteristics (age,gender, comorbidity status) and death and/or intensive care unit admission during hospitalization

    Time: february 23 to march 31, 2020

    Description: to identify laboratory variables as predictors of severe prognosis (death or intensive care unit admission) during hospitalization

    Measure: laboratory parameters (glycated hemoglobin, glucose at admission, renal and liver function markers, blood count, inflammatory markers, hemostasis) and death and/or intensive care unit admission during hospitalization

    Time: february 23 to march 31, 2020

    Description: to identify pharmacological therapies as predictors of severe prognosis (death or intensive care unit admission) during hospitalization

    Measure: pharmacological therapies and death and/or intensive care unit admission during hospitalization

    Time: february 23 to march 31, 2020

    Description: to compare total length of hospitalization in patients with or without diabetes

    Measure: number of days of hospitalization in patients with and without diabetes

    Time: february 23 to march 31, 2020
    17 Evaluation of Physical Activity, Quality of Life and Depression of Patients With Type 1 Diabetes Mellitus During the Covid-19 Pandemic

    During the COVID-19 pandemic, the time spent at the home of patients has increased because of national quarantine policies and patients' fear of getting sick. For this reason, in this ongoing process, patients have been unable to go to work regularly due to their chronic diseases (being on administrative leave) and their fear of going out. These reasons have prevented being physically active. The aim of the study is to evaluate the physical activity level, quality of life, glucose control, anxiety, depression, fear of hypoglycemia and loneliness perceptions of patients with type 1 diabetes mellitus during the COVID-19 pandemic period and compared with healthy controls.

    NCT04558645
    Conditions
    1. Type 1 Diabetes Mellitus
    2. Covid19
    Interventions
    1. Other: Online Survey
    MeSH:Diabetes Mellitus Diabetes Mellitus, Type 1
    HPO:Diabetes mellitus Type I diabetes mellitus

    Primary Outcomes

    Description: Physical activity level using International Physical Activity Questionnaire - Short Form (IPAQ-SF) will be evaluated.

    Measure: Physical activity level

    Time: Five minutes

    Description: Quality of life using Short Form Health Survey (SF-36) will be evaluated.

    Measure: General Quality of life

    Time: Ten minutes

    Secondary Outcomes

    Description: Depression using Hospital Anxiety and Depression Scale will be evaluated.

    Measure: Depression

    Time: Three minutes

    Description: Anxiety using Hospital Anxiety and Depression Scale will be evaluated.

    Measure: Anxiety

    Time: Three minutes

    Description: It will be questioned how many times patients have had hypoglycemic attacks (<4 mmol/L and common symptoms) in the last 7 days.

    Measure: Self-reported hypoglycemia

    Time: Last seven day

    Description: Loneliness using UCLA Loneliness Scale Short Form (ULS-8) will be evaluated.

    Measure: Loneliness

    Time: Three minutes

    Description: Hypoglisemia fear using Hypoglisemia Fear Survey (HFS) will be evaluated.

    Measure: Hypoglisemia fear

    Time: Five minutes

    Description: Dyspnea during daily life activites using Modified Medical Research Dyspnea Scale will be evaluated.

    Measure: Dyspnea

    Time: Two minutes
    18 Health-related Outcomes and Behaviour Changes in a Cohort of Diabetic Population During COVID-19 Pandemic: Results of a Telephonic Survey

    Diabetes management and follow-up has become a challenge during the COVID-19 pandemic. Nation-wide lockdowns and social distancing measures adopted in an attempt to break the chain of COVID-19 transmission have significantly disrupted routine care and follow-up of diabetes. In the health sector, especially in low-income countries such as Pakistan, there has been a shift of resources and staff reassignment from stable chronic illnesses to support COVID-19 pandemic. Disruption of routine outpatient health services and travel restrictions increase the risk of worsening diabetes control and diabetes-related health outcomes. Additionally, social isolation amidst an atmosphere of fear and uncertainty contributes to stress further affecting glycaemic control.

    NCT04573335
    Conditions
    1. Diabetes
    2. Covid19
    3. Isolation, Social
    MeSH:Diabetes Mellitus
    HPO:Diabetes mellitus

    Primary Outcomes

    Description: Death due to diabetes-related complications or otherwise

    Measure: All-cause mortality

    Time: during 3months of lockdown

    Secondary Outcomes

    Description: %age of participants with one or more symptoms of fever, sore throat, cough, dyspnoea

    Measure: COVID-19 illness

    Time: During 3months of lockdown
    19 Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19

    The COVID-19 pandemic has triggered extremely high hospitalization rates where mitigation strategies are urgently necessary to aid vulnerable Hispanic and Latino populations who are experiencing health disparities as well as high type 2 diabetes (T2D) prevalence with poor clinical outcomes when compared to non-Hispanic populations. The supplemental Dulce Digital-COVID Aware (DD-CA) intervention addresses specific barriers in diverse underserved Hispanic and Latino communities to improve glucose control and lower transmission of COVID-19 during a highly vulnerable period post hospitalization discharge, to reduce hospital readmission rates. This supplement will integrate COVID educational messaging with glucose management messaging within a low-cost, easily adoptable digital texting platform and offer critical information in a culturally and linguistically relevant manner to address specific barriers in diverse underserved communities.

    NCT04591015
    Conditions
    1. Diabetes Mellitus, Type 2
    2. Covid19
    Interventions
    1. Behavioral: Hospital: DD-CA
    2. Behavioral: Hospital: Usual Care (UC)
    MeSH:Diabetes Mellitus Diabetes Mellitus, Type 2
    HPO:Diabetes mellitus Type II diabetes mellitus

    Primary Outcomes

    Description: The Electronic Medical Record (EMR) will be used to identify readmissions during each patient's unique follow up period. Unadjusted between group differences will first be analyzed by comparing proportion of patients with any hospital readmissions within the 30-day period by a Fisher's exact test. Followup analyses will be conducted using multiple logistic regression models to account for gender, ethnicity, race, comorbid conditions including COVID-19, medication use, and baseline glycemic control, in addition to study arm, as fixed effects in predicting the primary outcome, rate of readmissions within 30-days. We do not anticipate missing data for covariates included in regression models since demographic data will be captured directly from the EMR, and baseline glycemic control (i.e. HbA1c at hospital admission) and COVID-19 diagnosis will be determined during the admission of study enrollment.

    Measure: Readmission rate (30-days)

    Time: 30-days

    Description: Additional metrics of glycemic control will be captured for each study participant from the EMR including HbA1c at 90-days post-discharge. Unadjusted group mean differences in HbA1c will be assessed with a students t-test, followed by multiple linear regression analysis controlling for baseline HbA1c (at time of initial admission), as well as covariates including gender, ethnicity, race, comorbid conditions including COVID-19, and medication/steriod use, in addition to study arm, as fixed effects in predicting HbA1c at 90 days.

    Measure: Glycosylated Hemoglobin (HbA1c)

    Time: Baseline, 90-days

    Secondary Outcomes

    Description: Diabetes distress will be measured using the Diabetes Distress Scale (DDS); range 1-6, with higher scores indicating worse outcomes/greater diabetes-related emotional stress. The survey will be administered immediately post enrollment, prior to randomizing, and during the 90-day follow-up visit. Measures will be compared between groups by t-tests at each time point.

    Measure: Diabetes Distress Scale

    Time: Baseline, 90-days

    Description: Research assistants will deliver the COVID-19 Patient Survey (PhenixToolkit) to each participant at their 90-day follow up to obtain their COVID-19 diagnosis status to determine whether any new infections occurred in the 90-day post-discharge time frame. Additional questions in the survey will be used for descriptive analyses to characterize infections. Differences in proportions of patients experiencing new infections per group (i.e. patients who were negative at discharge but had a self-reported positive test within 90 days) will be compared by Fisher's exact tests.

    Measure: COVID-19 Patient Survey

    Time: 90-days

    Description: Summary of Diabetes Self-Care Activities (SDSCA; range 0-7, with higher scores indicating better outcomes/greater adherence to diabetes self-management behaviors) will be administered immediately post enrollment, prior to randomizing, and during the 90-day follow-up visit. Measures will be compared between groups by t-tests at each time point.

    Measure: Summary of Diabetes Self-Care Activities Survey

    Time: Baseline, 90-days

    Description: Patient-Reported Outcomes Measurement Information System (PROMIS) Global-10 (range 0-100, with higher scores reflecting better outcomes/higher quality of life) will be administered immediately post enrollment, prior to randomizing, and during the 90-day follow-up visit. Measures will be compared between groups by t-tests at each time point.

    Measure: PROMIS Quality of Life Scale

    Time: Baseline, 90-days

    Description: Knowledge, Attitudes and Practices Toward COVID-19 Survey (range 0-12, with higher scores reflecting better knowledge of COVID-19) will be administered immediately post enrollment, prior to randomizing, and during the 90-day follow-up visit. Measures will be compared between groups by t-tests at each time point.

    Measure: Knowledge, Attitudes and Practice Toward COVID-19 Survey

    Time: Baseline, 90-days

    Description: Socio-Economic Status (SES), nativity, duration of US residence, Marital status, depressive symptoms and healthcare utilization will be measured immediately post enrollment, prior to randomizing.

    Measure: Demographics Questionnaire

    Time: Baseline

    Other Outcomes

    Description: Exploratory analyses will be conducted similarly to our Primary Outcome. The EMR will be used to identify readmissions during each patient's unique follow up period. Unadjusted between group differences will first be analyzed by comparing proportion of patients with any hospital readmissions within the 90-day period by a Fisher's exact t-test. Followup analyses will be conducted using multiple logistic regression models to account for gender, ethnicity, race, comorbid conditions including COVID-19, medication use, and baseline glycemic control, in addition to study arm, as fixed effects in predicting the exploratory outcome, rate of readmissions within 90-days.

    Measure: Readmission Rate (90-days)

    Time: 90-days
    20 The Effect of Diabetes Mellitus on the Morbidity and Mortality Rates in Patients With COVID-19

    All hospitalised patients with COVID-19 who have positive RT-PCR for SARS-COV-2 will be included in the study. The patients will be divided into two groups, as diabetics and non-diabetics. The COVID-19 patients' medical records will be evaluated and compared in terms of the duration of hospitalization, the presence of lung involvement in Computerised Tomography, the need for intensive care unit and mortality rates in patients with and without diabetes.

    NCT04591704
    Conditions
    1. Covid19
    2. Diabetes Mellitus
    Interventions
    1. Other: hospitalisation, necessity of ICU, mortality rate, lung involvement
    MeSH:Diabetes Mellitus
    HPO:Diabetes mellitus

    Primary Outcomes

    Description: The time between admission to hospital and discharge

    Measure: Duration of Hospitalisation

    Time: 1 year

    Description: The admission of hospitalized patients to the intensive care unit.

    Measure: The need for ICU

    Time: 1 year

    Description: Mortality rates of patients

    Measure: Mortality

    Time: 1 year

    Description: The presence of lung involvement on thorax CT

    Measure: Lung involvement

    Time: 1 year
    21 The Effect of COVID-19 on the Glycemic Control in Patients With Diabetes Mellitus

    The study aimed to evaluate the effect of SARS-COV-2 infection on metabolic status in patients with diabetes mellitus. Patients' HbA1c levels before and after SARS-COV-2 infection will be evaluated.

    NCT04592055
    Conditions
    1. Diabetes Mellitus
    2. Covid19
    MeSH:Diabetes Mellitus
    HPO:Diabetes mellitus

    Primary Outcomes

    Description: the change in A1c levels

    Measure: A1c

    Time: 6 months (3 months before and after COVID-19
    22 Technology-enabled Collaborative Care for Diabetes (TECC-Diabetes) Management During COVID: A Feasibility Study

    The overall goal of this research program is to evaluate the effectiveness of a Technology-Enabled Collaborative Care program. In this study, we examine the feasibility of such a program, called the Technology-Enabled Collaborative Care (TECC) for type 2 diabetes designed to support patients with diabetes and mental health concerns during COVID-19.

    NCT04607915
    Conditions
    1. Type 2 Diabetes
    Interventions
    1. Behavioral: Intervention for TECC Model
    MeSH:Diabetes Mellitus
    HPO:Diabetes mellitus

    Primary Outcomes

    Description: The primary outcome in this study is feasibility, specifically process outcomes. This includes assessing recruitment number

    Measure: Feasibility - Recruitment Numbers

    Time: Through the study completion, an average of 4 months

    Description: The primary outcome in this study is feasibility, specifically process outcomes. This includes participant characteristics

    Measure: Feasibility - Participant characteristics

    Time: up to 8-weeks

    Description: The primary outcome in this study is feasibility, specifically process outcomes. This includes participant retention rate (e.g., defined by time between first and last visit)

    Measure: Feasibility - Participant Engagement (retention rate)

    Time: up to 8-weeks

    Description: The primary outcome in this study is feasibility, specifically process outcomes. This includes intensity (e.g., number of session participants attend)

    Measure: Feasibility - Participant Engagement (intensity)

    Time: up to 8-weeks

    Description: The primary outcome in this study is feasibility, specifically process outcomes. This includes drop out (consented/enrolled but did not attend first one-on-one)

    Measure: Feasibility - Participant Engagement (drop out)

    Time: up to 8-weeks

    Description: The primary outcome in this study is feasibility, specifically process outcomes. This includes the amount of time a coach spends per interaction

    Measure: Feasibility - Delivery of Intervention (Time with coach)

    Time: up to 8-weeks

    Description: The primary outcome in this study is feasibility, specifically process outcomes. This includes the mode of the interaction (i.e., virtual, telephone or both)

    Measure: Feasibility - Delivery of Intervention (Mode of interaction)

    Time: up to 12-weeks

    Description: The primary outcome in this study is feasibility, specifically process outcomes. This includes what strategies are used by the coach (i.e., educational, psychosocial support, behaviour modifications, or case management/monitoring)

    Measure: Feasibility - Delivery of Intervention (Coach strategies)

    Time: up to 12-weeks

    Secondary Outcomes

    Description: The secondary outcome consists of study participant experience/satisfaction.

    Measure: Study Participant experience and satisfaction via semi-structured interview

    Time: up to 8-weeks

    Description: The secondary outcome consists of Care Coordinator experience and satisfaction.

    Measure: Care Coordinator experience and satisfaction via semi-structured interview

    Time: up to 8-weeks

    Description: The secondary outcome consists of Virtual Care Team experience and satisfaction.

    Measure: Virtual Care Team experience and satisfaction via semi-structured interview

    Time: up to 8-weeks

    Other Outcomes

    Description: The exploratory outcomes will include Health Behaviour metrics via International Physical Activity Questionnaire). Individual scores per question, the higher the score means the higher the level of physical activity.

    Measure: Exploratory Outcome - Health Behaviour metrics (physical activity)

    Time: up to 4-weeks

    Description: The exploratory outcomes will include Health Behaviour metrics (via Mediterranean Diet Adherence Screener Modified (MEDAS modified)

    Measure: Exploratory Outcome - Health Behaviour metrics (diet)

    Time: up to 4-weeks

    Description: The exploratory outcomes will include Health Behaviour metrics (via readiness to change ruler (smoking, alcohol, nutrition, physical activity). Minimum score: 0; maximum score: 10; higher score represented a better outcome.

    Measure: Exploratory Outcome - Health Behaviour metrics (confidence/importance to change behaviour)

    Time: up to 12-weeks

    Description: The exploratory outcomes will include substance use (via GAINS-SS (Global Appraisal of Individual Needs- Short Screener). Minimum score: 0; maximum score: 20; higher score represented a worse outcome.

    Measure: Exploratory Outcome - Substance Use (GAINS-SS)

    Time: up to 12-weeks

    Description: The exploratory outcomes will include substance use (Alcohol Use Disorders Identification Test (AUDIT); Minimum score: 0; maximum score: 40; higher score represented a worse outcome.

    Measure: Exploratory Outcome - Substance Use (alcohol)

    Time: up to 12-weeks

    Description: The exploratory outcomes will include substance use (via heaviness of smoking index - 2 items out of Fagerstrom test for nicotine dependence (FTND)); Minimum score: 0; maximum score: 6; higher score represented a worse outcome.

    Measure: Exploratory Outcome - Substance Use

    Time: up to 12-weeks

    Description: The exploratory outcomes will include Mental Health measures (via Patient Health Questionnaire (PHQ-9)). Minimum score: 0; maximum score: 27; higher score represented a worse outcome.

    Measure: Exploratory Outcome - Mental Health (depression)

    Time: up to 12-weeks

    Description: The exploratory outcomes will include Mental Health measures via Generalized Anxiety Disorder-7 (GAD-7). Minimum score: 0; maximum score: 21; higher score represented a worse outcome.

    Measure: Exploratory Outcome - Mental Health (Anxiety)

    Time: up to 12-weeks

    Description: The exploratory outcomes will include Mental Health measures via Diabetes awareness and insight scale. Minimum score: 0; maximum score: 10; higher score represented a better outcome.

    Measure: Exploratory Outcome - Mental Health (Diabetes awareness/insight)

    Time: up to 12-weeks

    Description: The exploratory outcomes will include Mental Health measures via Diabetes Distress Scale. Minimum score: 0; maximum score: 6; higher score represented a worse outcome.

    Measure: Exploratory Outcome - Mental Health (Diabetes Distress)

    Time: up to 12-weeks

    Description: The exploratory outcomes will include Mental Health measures via perceived stress scale (PSS). Minimum score: 0; maximum score: 40; higher score represented a worse outcome (i.e., higher perceived stress).

    Measure: Exploratory Outcome - Mental Health (Stress)

    Time: up to 12-weeks

    Description: The exploratory outcomes will include quality of life (via European Quality of Life - 5 Dimensions scale - EQ5D). Minimum score: 0; maximum score: 100; higher score represented a better outcome.

    Measure: Exploratory Outcome - Quality of Life

    Time: up to 12-weeks

    Description: The exploratory outcomes will include quality of life (via Verona satisfaction scale). Minimum score: 0; higher score represented a better outcome.

    Measure: Exploratory Outcome - Quality of Life

    Time: up to 12-weeks

    Description: self-report

    Measure: Exploratory Outcome - Waist circumference

    Time: up to 12-weeks

    Description: self-report

    Measure: Exploratory Outcome - BMI (height/weight)

    Time: up to 12-weeks

    Description: self-report

    Measure: Exploratory Outcome - Blood pressure

    Time: up to 12-weeks

    Description: list

    Measure: Exploratory Outcome - Current medication

    Time: up to 12-weeks

    Description: Hemoglobin A1C levels

    Measure: Exploratory Outcome - Blood work

    Time: up to 12-weeks

    Description: Brief Pain Inventory-sf. Minimum score: 0; maximum score: 10; higher score represented a worse outcome (i.e., more pain).

    Measure: Exploratory Outcome - Pain

    Time: up to 12-weeks

    Description: months

    Measure: Exploratory Outcome - Diabetes duration

    Time: up to 12-weeks

    Description: Diabetes Self-Management and Technology Questionnaire (DSMT-Q); Minimum score: 0; maximum score: 48; higher score represented a worse outcome.

    Measure: Exploratory Outcome - Diabetes self-management

    Time: up to 12-weeks
    23 Covid-19 and Type 1 Diabetes - a Multicenter Study

    Although recognized as an autoimmune disease the etiology of type 1 diabetes remains unknown. Virus infections has been suggested as a possible agent triggering the autoimmune reaction finally resulting in beta-cell destruction and fate of insulin secretion. SARS Cov-2 virus enters the infected cells by binding to the ACE-2 receptor, which is abundant in many tissues including the pancreas. Accordingly, SARS Covid-19 infection may trigger the development of type 1 diabetes either by an activation of the immune system or directly via beta-cell infection and destruction. Our aim is to study the impact of the Covid-19 epidemic on the development of type 1 diabetes. This will be done in two ways: a clinical study and an epidemiological follow up. During the next two years, adult patients with newly diagnosed type 1 diabetes will be asked to participate. Type 1 diabetes will be diagnosed by usual means and a mixed meal tolerance test will be performed at time of diagnosis and after one year to evaluate beta-cell function. People with type 1 diabetes and serologically documented previous SARS Covid-19 will be compared with people with no previous infection regarding beta-cell function and fate of insulin secretion. In addition, we will estimate the number of new diagnosed type 1 diabetes patients compared to previous years.

    NCT04623697
    Conditions
    1. Covid19
    2. type1diabetes
    MeSH:Diabetes Mellitus Diabetes Mellitus, Type 1
    HPO:Diabetes mellitus Type I diabetes mellitus

    Primary Outcomes

    Description: C-peptide AUC of the MMTT at baseline and one year follow-up

    Measure: Stimulated insulin secretion

    Time: One years

    Secondary Outcomes

    Description: HbA1c measure at one year

    Measure: HbA1c

    Time: One years

    Description: Fasting blood glucose

    Measure: Fasting blood glucose

    Time: One years
    24 Study on Characteristics and Prognosis of Diabetes and Non Diabetes Patients With COVID 19 Among Southern Indian Population

    There were 83,85,440 confirmed cases of COVID-19 worldwide with a mortality rate of 5.4% according to the situation report of the World Health Organisation on June 19, 2020. In India there were 3,95,048 confirmed cases of COVID-19 with a mortality rate of 3.3%. In Tamil Nadu there were 54,449 confirmed cases of COVID-19 with a mortality rate of 1.2% according to the report of Ministry of Health and Family Welfare, Government of India on June 19, 2020. COVID-19 infection is a double challenge for people with diabetes. India has a large number of persons with diabetes (more than 77 million). Recent studies have reported rising prevalence both in the urban and rural populations. The incidence of type 2 diabetes (T2D) also shows an increasing trend in the last few decades. Mortality seems to be threefold higher in people with diabetes when COVD-19 coexists when compared with mortality due to COVID-19 without comorbidities. Yang et al noted that among 52 intensive care patients who had COVID 19 infection, 22% had diabetes among the non-survivors. In a study of 173 patients with severe disease, 16.2% had diabetes, and in another study of 140 hospitalized patients, 12% had diabetes. Li et al compared intensive care and non-intensive care patients who had COVID-19. They showed a twofold increase in the incidence of diabetes in intensive care patients. In addition to diabetes; the other common co-morbidities present in COVID 19 patients were hypertension (20%), cardiovascular disease (16%), and lung disease (6%). In this context, patients with diabetes have been listed as people with higher severity for COVID-19 by several health authorities. However, precise data regarding patients with and without diabetes having COVID-19 infection are still lacking. Moreover, the relationship between diabetes and the severity of COVID-19 remains unknown. In this study, we intend to identify the disease severity and mortality in people with and without diabetes admitted for COVID-19 in southern India.

    NCT04634214
    Conditions
    1. Covid19
    2. Type2 Diabetes
    MeSH:Diabetes Mellitus
    HPO:Diabetes mellitus

    Primary Outcomes

    Description: To identify the disease severity and outcome among people with and without diabetes hospitalized for COVID 19 virus infection

    Measure: Severity of COVID 19 among people with and without diabetes

    Time: Up to 1 month

    Secondary Outcomes

    Description: Number of patients who were in ICU

    Measure: Number of patients who were in ICU

    Time: Up to 1 month

    Description: Number of patients who had tracheal intubation

    Measure: Number of patients who had tracheal intubation

    Time: Up to 1 month

    Description: Number of patients who had respiratory complication

    Measure: Number of patients who had respiratory complication

    Time: Up to 1 month

    Description: Number of death

    Measure: Number of death

    Time: Up to 1 month

    Description: Correlation of BMI with complications, tracheal intubation and mortality

    Measure: Correlation of BMI with complications, tracheal intubation and mortality

    Time: Up to 1 month

    Description: Length of hospital stay

    Measure: Length of hospital stay

    Time: Up to 1 month
    25 The Effect of Diabetes Mellitus on Mortality in Patients Hospitalized in the COVID Intensive Care Unit in the COVID-19 Pandemic

    The study includes patients over 18 years old who were hospitalized in our covid intensive care unit between March 16 and May 16, 2020. Retrospective records were examined by examining the electronic data files of the patients. Polymerase Chain Reaction (PCR) tests performed with nasopharyngeal swab taken from the person, which is the standard diagnostic method, and also the diagnosis of infection symptoms, risk factors and thoracic CT scans indicating pneumonia were diagnosed. Patients over 18 years of age with and without a medical history of DM in their history were identified and compared in 2 groups.

    NCT04663659
    Conditions
    1. Covid19
    2. Diabetes Mellitus
    Interventions
    1. Other: no intervention
    MeSH:Diabetes Mellitus
    HPO:Diabetes mellitus

    Primary Outcomes

    Description: Mortality rates of patients

    Measure: Mortality

    Time: 3 months

    Description: The time between admission to intensive care unit and discharge

    Measure: length of stay in intensive care

    Time: 3 months

    HPO Nodes


    HP:0000819: Diabetes mellitus
    Genes 567
    LHX1 BLK MERTK PROK2 UBR1 MTHFR MAGEL2 UBR1 NODAL ND6 NDUFS4 RETN TRNL1 MAGEL2 TRNK POLA1 GTF2IRD1 TRNC SLC7A14 RP1 HNF1A CTRC CAVIN1 BRAF RTL1 BBS1 FGFR1 PDE6A CNGB1 LIPE ZNF408 HNF1B TRNS2 GCK HNF4A SHH CTNNB1 BMP2 HYMAI DCAF17 PTF1A TOPORS CFTR KCNJ11 OCA2 SPINK1 ENPP1 AMACR MTNR1B ND1 TCF4 RBP3 ELMO2 PRSS1 SAG MAPK8IP1 PAX4 TP53 NDN FUZ DLL1 PROKR2 RTL1 PCNT SIM1 CLIP2 ABCC8 ELN KCTD1 PIK3R1 TTC7A IRS2 IGF1R GNAS EDA2R ABCC8 PIK3R1 OFD1 PLIN1 CNBP PEX10 COX1 ELN KLF11 SLC19A2 TULP1 LMNB2 PEX6 AKT2 NDUFV2 NDUFAF5 HFE GLIS3 SNRNP200 INS FOXP3 HMGA1 LIPE TRMT10A XRCC4 NEUROD1 HESX1 PTRH2 MTHFR PDE4D NSMCE2 GLRX5 HAMP HNF1B TRNW NPAP1 PPARG SUFU RP9 IFT88 IRS1 RHO PLAGL1 BLM TDGF1 PRSS1 AKT2 PDX1 TRNW ARL3 RPGR HNF4A GPD2 LMNA PDE6B USB1 MEG3 NDUFB10 SNORD115-1 ZNF513 DNAJC21 WFS1 XRCC4 SOX3 SLC25A4 IL2RA RLBP1 NDUFA11 MKRN3-AS1 PRKAR1A NDUFS3 HJV TKT FAM161A GCK LIG4 ROM1 GJA1 TRNS1 TRNH BLM COX1 SNRPN TTC8 PDE8B AGPAT2 TREX1 TINF2 LMNA AIP DCAF17 ND2 IFIH1 BRCA1 IDH3B DNM1L PDE4D GJB4 USP8 BEST1 PWRN1 GATA6 IPW RP2 ND1 GATA6 ARNT2 SLC19A2 APPL1 ND4 PDX1 FOXRED1 TRNF STAT1 INSR IMPDH1 GATA3 SLC2A2 DHDDS EIF2S3 IL6 CNOT1 HLA-DRB1 GPR101 PPARG TRNQ GCK RPE65 ATP6 SNRPN ZBTB20 CISD2 TRNS1 INS CAT SPATA7 RAC1 NDUFB11 HNF4A PALLD RNASEH2B TRNE XRCC4 NDUFAF8 ARHGEF18 STAT1 CYTB LIPC GCK EDA HBB MMP2 OCA2 ZFYVE26 FOXP3 TRNF KLHL7 ALMS1 CP SEMA4A USH2A FGF8 SBDS HBB CERKL INS CYP19A1 APPL1 RNASEH2A TRNS2 ZFP57 GJA1 CDON TIMMDC1 FGFR1 POLR3A AGPAT2 MAGEL2 HNF4A ZFP57 ND1 FOXH1 PRPF8 IARS1 SPINK1 PAX4 HNF1A NDUFAF3 GAS1 CDHR1 NPM1 STUB1 PWAR1 CPA1 KCNJ11 EYS HNF1A IL18BP DISP1 PDX1 VANGL1 CEP19 POLG2 CARS1 CLRN1 HNF1B NDN MKRN3 KCNJ11 BSCL2 OCA2 ZIC2 SRP54 CAV1 CFTR DHX38 IFT172 PPARG FXN WRN PLIN1 INSR WRN NDUFB9 WFS1 DLK1 MMP14 LEP PTPN1 ARL2BP PRCD EIF2AK3 CIDEC ITCH PRPH2 CDH23 NEK2 ATM PTRH2 TTPA SLC29A3 NDN NKX2-5 PDE11A NDUFS8 REEP6 AGBL5 ZMPSTE24 PROM1 NDUFS6 TRNK AEBP1 PRSS2 LEPR TBL2 BBS2 COL2A1 LRP6 GCK POC1A PDX1 CTNS CORIN PNPLA2 IFT140 PPP1R15B FOXP1 RFC2 CTRC NDUFS1 LMNA PTPN22 SNORD116-1 LEPR RNASEH2C RRM2B LIMK1 BLK NOTCH3 HMGA2 TWNK CNOT1 FLT1 NEUROD1 KCNJ11 ABCA4 IDH3A CDKN2A NDUFA6 KIZ ABCC8 ATM BRCA2 ND6 NDUFS2 LMNA ND3 IMPG2 MST1 TGIF1 PAX4 WFS1 KCNJ11 FXN NOP10 KDSR MEG3 OPA1 TRNQ TUB HYMAI CISD2 DNAJC3 STOX1 IL2RA NDUFS7 NDUFA1 NUBPL BSCL2 PEX1 COX2 SPINK1 PAX4 RTEL1 INS NDUFB3 COX3 CASR SMAD4 GCK ITPR3 SNRPN HBB POLG NDP OTX2 SLC12A3 TRNE PNPLA6 APOA5 LMNA GCK STAT3 POMGNT1 PDE6G WFS1 GLI2 CLCNKB ALMS1 AHI1 LEMD3 HNF1A BBS2 GJB3 ABCC8 TP53 ITCH RP1L1 PLAGL1 LMNA PALB2 NDUFAF2 CRB1 CNGA1 DMPK PPP1R3A PNPLA2 PTCH1 WRAP53 STAT3 SAMHD1 HYMAI NDUFV1 HGSNAT HNF1B HNF4A SLC29A3 ARMC5 CCDC28B KRAS GTF2I MAGEL2 TWNK HNF1A PRPF3 VANGL2 GUCA1B TMEM126B EIF2AK3 TRNV TERT KCNJ11 PTF1A FBN1 IGF2BP2 ARL6 COX2 HFE AIP NR2E3 PCARE MAK KCNJ11 HLA-DQB1 ABCC8 NDN PLCD1 NDUFAF4 POLD1 CEL VANGL2 NSMCE2 PSTPIP1 SOX2 SIX3 ND5 TCF7L2 NEUROG3 MKKS CAV1 SMPD4 SLC16A2 PDX1 FSCN2 PRKACA CA4 MC4R TRNL1 PRKACA CTC1 ADA2 PRSS2 SNRPN RGR AHR DMXL2 PRPF4 KLF11 ADAR SARS2 MOG MEN1 HERC2 CP ND5 INSR LRAT MAFA EFL1 HNF1A TERC FOXC2 SCAPER FOS CRX DLK1 KIAA1549 MAGEL2 MLXIPL DNAJC3 PRPF31 AIRE PRPF6 PARN DKC1 NEUROD1 APOE PPARG WFS1 ABCC8 LRBA AR NRL NHP2 GPR35 BAZ1B RDH12 ERGIC1 ARL6 NDUFAF1 SLC30A8 PDX1 COX3 ABCC8 INS C8ORF37 IER3IP1 PRKAR1A KCNJ11 CEL INS TRNL1

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0000819: Diabetes mellitus
    Genes 567
    LHX1 BLK MERTK PROK2 UBR1 MTHFR MAGEL2 UBR1 NODAL ND6 NDUFS4 RETN TRNL1 MAGEL2 TRNK POLA1 GTF2IRD1 TRNC SLC7A14 RP1 HNF1A CTRC CAVIN1 BRAF RTL1 BBS1 FGFR1 PDE6A CNGB1 LIPE ZNF408 HNF1B TRNS2 GCK HNF4A SHH CTNNB1 BMP2 HYMAI DCAF17 PTF1A TOPORS CFTR KCNJ11 OCA2 SPINK1 ENPP1 AMACR MTNR1B ND1 TCF4 RBP3 ELMO2 PRSS1 SAG MAPK8IP1 PAX4 TP53 NDN FUZ DLL1 PROKR2 RTL1 PCNT SIM1 CLIP2 ABCC8 ELN KCTD1 PIK3R1 TTC7A IRS2 IGF1R GNAS EDA2R ABCC8 PIK3R1 OFD1 PLIN1 CNBP PEX10 COX1 ELN KLF11 SLC19A2 TULP1 LMNB2 PEX6 AKT2 NDUFV2 NDUFAF5 HFE GLIS3 SNRNP200 INS FOXP3 HMGA1 LIPE TRMT10A XRCC4 NEUROD1 HESX1 PTRH2 MTHFR PDE4D NSMCE2 GLRX5 HAMP HNF1B TRNW NPAP1 PPARG SUFU RP9 IFT88 IRS1 RHO PLAGL1 BLM TDGF1 PRSS1 AKT2 PDX1 TRNW ARL3 RPGR HNF4A GPD2 LMNA PDE6B USB1 MEG3 NDUFB10 SNORD115-1 ZNF513 DNAJC21 WFS1 XRCC4 SOX3 SLC25A4 IL2RA RLBP1 NDUFA11 MKRN3-AS1 PRKAR1A NDUFS3 HJV TKT FAM161A GCK LIG4 ROM1 GJA1 TRNS1 TRNH BLM COX1 SNRPN TTC8 PDE8B AGPAT2 TREX1 TINF2 LMNA AIP DCAF17 ND2 IFIH1 BRCA1 IDH3B DNM1L PDE4D GJB4 USP8 BEST1 PWRN1 GATA6 IPW RP2 ND1 GATA6 ARNT2 SLC19A2 APPL1 ND4 PDX1 FOXRED1 TRNF STAT1 INSR IMPDH1 GATA3 SLC2A2 DHDDS EIF2S3 IL6 CNOT1 HLA-DRB1 GPR101 PPARG TRNQ GCK RPE65 ATP6 SNRPN ZBTB20 CISD2 TRNS1 INS CAT SPATA7 RAC1 NDUFB11 HNF4A PALLD RNASEH2B TRNE XRCC4 NDUFAF8 ARHGEF18 STAT1 CYTB LIPC GCK EDA HBB MMP2 OCA2 ZFYVE26 FOXP3 TRNF KLHL7 ALMS1 CP SEMA4A USH2A FGF8 SBDS HBB CERKL INS CYP19A1 APPL1 RNASEH2A TRNS2 ZFP57 GJA1 CDON TIMMDC1 FGFR1 POLR3A AGPAT2 MAGEL2 HNF4A ZFP57 ND1 FOXH1 PRPF8 IARS1 SPINK1 PAX4 HNF1A NDUFAF3 GAS1 CDHR1 NPM1 STUB1 PWAR1 CPA1 KCNJ11 EYS HNF1A IL18BP DISP1 PDX1 VANGL1 CEP19 POLG2 CARS1 CLRN1 HNF1B NDN MKRN3 KCNJ11 BSCL2 OCA2 ZIC2 SRP54 CAV1 CFTR DHX38 IFT172 PPARG FXN WRN PLIN1 INSR WRN NDUFB9 WFS1 DLK1 MMP14 LEP PTPN1 ARL2BP PRCD EIF2AK3 CIDEC ITCH PRPH2 CDH23 NEK2 ATM PTRH2 TTPA SLC29A3 NDN NKX2-5 PDE11A NDUFS8 REEP6 AGBL5 ZMPSTE24 PROM1 NDUFS6 TRNK AEBP1 PRSS2 LEPR TBL2 BBS2 COL2A1 LRP6 GCK POC1A PDX1 CTNS CORIN PNPLA2 IFT140 PPP1R15B FOXP1 RFC2 CTRC NDUFS1 LMNA PTPN22 SNORD116-1 LEPR RNASEH2C RRM2B LIMK1 BLK NOTCH3 HMGA2 TWNK CNOT1 FLT1 NEUROD1 KCNJ11 ABCA4 IDH3A CDKN2A NDUFA6 KIZ ABCC8 ATM BRCA2 ND6 NDUFS2 LMNA ND3 IMPG2 MST1 TGIF1 PAX4 WFS1 KCNJ11 FXN NOP10 KDSR MEG3 OPA1 TRNQ TUB HYMAI CISD2 DNAJC3 STOX1 IL2RA NDUFS7 NDUFA1 NUBPL BSCL2 PEX1 COX2 SPINK1 PAX4 RTEL1 INS NDUFB3 COX3 CASR SMAD4 GCK ITPR3 SNRPN HBB POLG NDP OTX2 SLC12A3 TRNE PNPLA6 APOA5 LMNA GCK STAT3 POMGNT1 PDE6G WFS1 GLI2 CLCNKB ALMS1 AHI1 LEMD3 HNF1A BBS2 GJB3 ABCC8 TP53 ITCH RP1L1 PLAGL1 LMNA PALB2 NDUFAF2 CRB1 CNGA1 DMPK PPP1R3A PNPLA2 PTCH1 WRAP53 STAT3 SAMHD1 HYMAI NDUFV1 HGSNAT HNF1B HNF4A SLC29A3 ARMC5 CCDC28B KRAS GTF2I MAGEL2 TWNK HNF1A PRPF3 VANGL2 GUCA1B TMEM126B EIF2AK3 TRNV TERT KCNJ11 PTF1A FBN1 IGF2BP2 ARL6 COX2 HFE AIP NR2E3 PCARE MAK KCNJ11 HLA-DQB1 ABCC8 NDN PLCD1 NDUFAF4 POLD1 CEL VANGL2 NSMCE2 PSTPIP1 SOX2 SIX3 ND5 TCF7L2 NEUROG3 MKKS CAV1 SMPD4 SLC16A2 PDX1 FSCN2 PRKACA CA4 MC4R TRNL1 PRKACA CTC1 ADA2 PRSS2 SNRPN RGR AHR DMXL2 PRPF4 KLF11 ADAR SARS2 MOG MEN1 HERC2 CP ND5 INSR LRAT MAFA EFL1 HNF1A TERC FOXC2 SCAPER FOS CRX DLK1 KIAA1549 MAGEL2 MLXIPL DNAJC3 PRPF31 AIRE PRPF6 PARN DKC1 NEUROD1 APOE PPARG WFS1 ABCC8 LRBA AR NRL NHP2 GPR35 BAZ1B RDH12 ERGIC1 ARL6 NDUFAF1 SLC30A8 PDX1 COX3 ABCC8 INS C8ORF37 IER3IP1 PRKAR1A KCNJ11 CEL INS TRNL1

    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook